Generate Biomedicines, Inc. Common Stock GENB
$16.14
-20.80%
at last close
Analyst Consensus
- Consensus Rating
- Buy (6 Buy · 0 Hold · 0 Sell)
- Average Price Target
- $25.40
- Implied Upside
- +57.4%
- Price Target Range
- $22.00 – $30.00
- Analysts (12 mo)
- 6
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-05-14 | Morgan StanleySean Laaman |
Maintains | Overweight | $20 → $22 |
| 2026-05-08 | HC Wainwright & Co.Mitchell S. Kapoor |
Maintains | Buy | $16 → $25 |
| 2026-04-13 | HC Wainwright & Co.Mitchell S. Kapoor |
Initiates coverage on | Buy | $16 |
| 2026-03-24 | Goldman SachsSalveen Richter |
Initiates coverage on | Buy | $26 |
| 2026-03-24 | Morgan StanleySean Laaman |
Initiates coverage on | Overweight | $20 |
| 2026-03-24 | Piper SandlerEdward Tenthoff |
Initiates coverage on | Overweight | $24 |
| 2026-03-24 | Cantor FitzgeraldEric Schmidt |
Initiates coverage on | Overweight | — |
| 2026-03-24 | GuggenheimSeamus Fernandez |
Initiates coverage on | Buy | $30 |
Ratings and price targets reflect each firm's most recent published action. Consensus combines the latest call from every covering firm over the past 12 months; price targets are typically 12-month horizons.
Key Stats
- Last Close
- $16.14
- Market Cap
- $2.62 billion
- 52-Week Range
- $11.00 – $22.67
- Average Volume
- 875K shs
Data is delayed and provided for informational purposes only. Not investment advice. See our disclaimer.